{
    "code": "02025308",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02025308",
    "time": "2021-12-17 03:28:41",
    "許可證字號": "衛署藥輸字第025308號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "114\/12\/08",
    "發證\/登錄日期": "99\/12\/08",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA00202530806",
    "中文品名": "必新胰長效錠 500 毫克",
    "英文品名": "BIGSENS-XR 500 TABLETS",
    "適應症": "第二型糖尿病。",
    "劑型": "129長效錠",
    "包裝": "2~1000錠塑膠瓶裝 AL\/PVC-PVDC 鋁箔盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "METFORMIN HCL (EQ TO METFORMIN HYDROCHLORIDE)",
    "限制項目": "02輸　入 25監視中學名藥",
    "申請商名稱": "640102B347  毅有生技醫藥股份有限公司",
    "申請商地址": "新北市中和區中山路２段332巷37號13樓",
    "主製造廠": [
        {
            "": "INDIA",
            "製程": ""
        }
    ],
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "6820400710",
            "成分名稱": "METFORMIN HCL (EQ TO METFORMIN HYDROCHLORIDE)",
            "含量描述": "",
            "含量": "500.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "仿單-104-12-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025308&Seq=003&Type=9"
        },
        {
            "title": "必新胰長效錠500毫克-鋁箔包裝實體照片-104-09-30(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025308&Seq=002&Type=8"
        }
    ]
}